140 related articles for article (PubMed ID: 26599391)
1. Menopausal hormone therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer, Lifestyle and Evaluation of Risk study.
Salagame U; Banks E; Sitas F; Canfell K
Int J Cancer; 2016 Apr; 138(8):1905-14. PubMed ID: 26599391
[TBL] [Abstract][Full Text] [Related]
2. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.
Collaborative Group on Hormonal Factors in Breast Cancer
Lancet; 2019 Sep; 394(10204):1159-1168. PubMed ID: 31474332
[TBL] [Abstract][Full Text] [Related]
3. Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort.
Obi N; Heinz J; Seibold P; Vrieling A; Rudolph A; Chang-Claude J; Berger J; Flesch-Janys D
Int J Cancer; 2016 May; 138(9):2098-108. PubMed ID: 26649645
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer and hormone-replacement therapy in the Million Women Study.
Beral V;
Lancet; 2003 Aug; 362(9382):419-27. PubMed ID: 12927427
[TBL] [Abstract][Full Text] [Related]
5. Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: Results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study.
Salagame U; Banks E; O'Connell DL; Egger S; Canfell K
PLoS One; 2018; 13(11):e0205034. PubMed ID: 30403669
[TBL] [Abstract][Full Text] [Related]
6. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France.
Cordina-Duverger E; Truong T; Anger A; Sanchez M; Arveux P; Kerbrat P; Guénel P
PLoS One; 2013; 8(11):e78016. PubMed ID: 24223752
[TBL] [Abstract][Full Text] [Related]
7. Is breast cancer risk the same for all progestogens?
Stute P
Arch Gynecol Obstet; 2014 Aug; 290(2):207-9. PubMed ID: 24838289
[TBL] [Abstract][Full Text] [Related]
8. Menopausal hormone therapy and cancer risk: An overestimated risk?
Simin J; Tamimi R; Lagergren J; Adami HO; Brusselaers N
Eur J Cancer; 2017 Oct; 84():60-68. PubMed ID: 28783542
[TBL] [Abstract][Full Text] [Related]
9. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?
Jones ME; Schoemaker MJ; Wright L; McFadden E; Griffin J; Thomas D; Hemming J; Wright K; Ashworth A; Swerdlow AJ
Br J Cancer; 2016 Aug; 115(5):607-15. PubMed ID: 27467055
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Jan; 119(2):463-74. PubMed ID: 19424794
[TBL] [Abstract][Full Text] [Related]
11. Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
Cadeau C; Fournier A; Mesrine S; Clavel-Chapelon F; Fagherazzi G; Boutron-Ruault MC
Int J Cancer; 2016 Nov; 139(10):2193-200. PubMed ID: 27451078
[TBL] [Abstract][Full Text] [Related]
12. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
Beral V; Bull D; Reeves G;
Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
[TBL] [Abstract][Full Text] [Related]
13. Association between menopausal hormone therapy, mammographic density and breast cancer risk: results from the E3N cohort study.
Fornili M; Perduca V; Fournier A; Jérolon A; Boutron-Ruault MC; Maskarinec G; Severi G; Baglietto L
Breast Cancer Res; 2021 Apr; 23(1):47. PubMed ID: 33865453
[TBL] [Abstract][Full Text] [Related]
14. Use of Menopausal Hormone Therapy and Bioidentical Hormone Therapy in Australian Women 50 to 69 Years of Age: Results from a National, Cross-Sectional Study.
Velentzis LS; Banks E; Sitas F; Salagame U; Tan EH; Canfell K
PLoS One; 2016; 11(3):e0146494. PubMed ID: 27008039
[TBL] [Abstract][Full Text] [Related]
15. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials.
Greiser CM; Greiser EM; Dören M
Hum Reprod Update; 2005; 11(6):561-73. PubMed ID: 16150812
[TBL] [Abstract][Full Text] [Related]
16. Risk of venous thromboembolism in users of hormone replacement therapy.
Daly E; Vessey MP; Hawkins MM; Carson JL; Gough P; Marsh S
Lancet; 1996 Oct; 348(9033):977-80. PubMed ID: 8855852
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.
Hein R; Abbas S; Seibold P; Salazar R; Flesch-Janys D; Chang-Claude J
Breast Cancer Res Treat; 2012 Jan; 131(2):653-61. PubMed ID: 21947678
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT).
Sourander L; Rajala T; Räihä I; Mäkinen J; Erkkola R; Helenius H
Lancet; 1998 Dec 19-26; 352(9145):1965-9. PubMed ID: 9872245
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.
MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk
Breast Cancer Res Treat; 2010 Apr; 120(3):727-36. PubMed ID: 19672706
[TBL] [Abstract][Full Text] [Related]
20. The risk of breast cancer linked to menopausal hormone therapy.
Sæther S; Bakken K; Lund E
Tidsskr Nor Laegeforen; 2012 Jun; 132(11):1330-4. PubMed ID: 22717857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
